Pharma The President of Cristers discusses the history of generic drugs in France and what steps can be taken to increase generics penetration, while also outlining the ‘cooperative’ business model behind Cristers’ meteoric rise – with a sixty-fold increase in turnover in less than a decade – from its creation in…
Pharma Yves Bur reveals how the motivation behind his political engagement has been to raise awareness around the importance of improving the social security system. Bur also explains why having a real public health policy is another way of combatting the increase in health spending, and how France needs to reach…
Pharma The General Manager of LEEM talks about the association’s strategy based on three key points, innovation, attractiveness and efficiency; how the Mediator affair has placed a question mark on the championing of the pharma industry as a national asset; why both France and Europe are at turning point and what…
innovation Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research industry and stresses the importance of knowledge-sharing for success. What have been some of the most important changes made…
France Sandoz has set important trends in the pharmaceutical market, first by creating a leading global generics business under the umbrella of parent company Novartis, and secondly by investing heavily in biosimilars, becoming a pioneer in a fast-growing niche. How have these two steps helped reshape Sandoz internally? With the creation…
France What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that we can no longer live during this crisis without letting people express themselves genuinely. And I don’t mean expression of…
See our Cookie Privacy Policy Here